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Summary: Purpose: Adenosine is a neuromodulator that has
been proposed to act as an anticonvulsant mainly via inhibitory
A1 receptors, but recent data show that genetic deletion of fa-
cilitatory A2A receptors might also attenuate convulsions. Since
both A1 and A2A receptors are prone to down- and upregulation
in different stressful situations, we investigated if convulsive be-
havior leads to a long-term change in A1 and A2A receptor density
in the rat cerebral cortex.
Methods: Stage 4-5 convulsions (Racine’s scale) were induced
in adult Wistar rats either through amygdala stimulation (kin-
dling) or by intraperitoneal injection of kainate (10 mg/ml). Rats
were killed after 4 weeks to evaluate adenosine A1 and A2A re-
ceptor density in the cerebral cortex using both Western blot and
membrane binding assays.
Results: The binding density of the A1 antagonist, 3H-DPCPX,
decreased by 40. ± 4.4% and by 20.7 ± 0.5% after kindling or
kainate injection. Likewise, A1 receptor immunoreactivity in cor-
tical membranes from kindled or kainate-injected rats decreased
by 19.1 ± 3.3% and 12.7 ± 5.7%, respectively. In contrast, the
binding density of the A2A receptor antagonist 3H-SCH 58261
increased by 293 ± 34% and by 159 ± 32% in cortical mem-
branes from kindled or kainate-injected rats, and A2A receptor
immunoreactivity also increased by 151±12% and 79.6±7.0%.
Conclusions: This indicates that after convulsive behavior
there is a long-term decrease of A1 receptors accompanied by an
increased density of A2A receptors, suggesting that A2A antag-
onists rather than A1 agonists may be more promising anticon-
vulsive drugs. Key Words: Adenosine—Cortex—Kindling—
Kainate—Epilepsy—A1 receptor—A2A receptor.
Adenosine is a ubiquitous neuromodulator that mainly
inhibits synaptic transmission and neuronal excitability
through activation of the predominant adenosine A1 re-
ceptors (1). The ability of adenosine to selectively depress
glutamatergic excitatory pathways makes A1 receptors in-
teresting anticonvulsant targets [reviewed in (2)]. Accord-
ingly, exogenous administration of A1 receptor agonists
attenuates seizures, and the use of A1 receptor antagonists
has proconvulsant effects [reviewed in (2)]. It has even
been proposed that the loss of the A1 receptor-mediated
control of glutamatergic function could contribute to the
implementation of epileptic status (3). However, conflict-
ing results have been reported in relation to the impact of
convulsive behavior on cortical A1 receptors [reviewed in
(4)]. In other brain regions, chronic stressful situations,
such as amygdala kindling (5) or Alzheimer’s disease (6),
decreased the density of A1 receptors.
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Adenosine can also activate another less abundant
adenosine receptor subtype, i.e., A2A receptors, with ef-
fects generally opposite to these mediated by A1 receptors
(7). These facilitatory A2A receptors are most abundant in
the basal ganglia and have a density 20 times lower in the
cerebral cortex (8). However, despite their low abundance,
and by mechanisms still to be resolved, pharmacological
blockade or genetic inactivation of these A2A receptors
confer robust neuroprotection in the limbic and neocortex
in different noxious brain situations [reviewed in (9)]. In
particular, genetic inactivation of A2A receptors decreases
ethanol withdrawal-induced seizures (10), suggesting a
role for A2A receptors also in the control of convulsive
behavior. Interestingly, studies in nonbrain preparations
have documented that prolonged stressful situations, such
as hypoxia (11) or exposure to cytokines (12), enhance the
expression and density of these A2A receptors, but this has
not yet been documented in brain tissue.
Therefore, there is ground to consider both A1 and A2A
receptors as possible targets for the development of an-
ticonvulsants. However, since noxious situations lead to
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changes in the density of both A1 and A2A receptors, it ap-
pears necessary to determine if the occurrence of seizures
might also lead to changes in A1 and A2A receptor den-
sities. Thus, this study was designed to investigate the
long-term changes of the densities of A1 and A2A recep-
tors in the cerebral cortex using two different strategies to
induce episodic convulsive behavior: amygdala kindling
(13) and intraperitoneal injection of kainate (14).
METHODS
Reagents
3H-1,3-Dipropyl-8-cyclopentyladenosine(3H-DPCPX,
specific activity 109.0 Ci/mmol) was from DuPont
NEN (Anagene, Portugal), and 3H-5-amino-7-(2-pheny-
lethyl)-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]
pyrimidine (3H-SCH 58261, specific activity 77 Ci/mmol)
was prepared by Amersham (Buckinghamshire, U.K.)
and was a generous gift of Dr. Ennio Ongini (Shering-
Plough, Milan, Italy). Kainate and adenosine deaminase
(calf intestine suspension, 2000 U/ml, EC 3.5.4.4) were
from Sigma (Reagente 5, Oporto, Portugal), 8-{4-[(2-
aminoethyl)amino]carbonylmethyl-oxyphenyl}xanthine
(XAC) was from Research Biochemical International
(Reagente 5, Oporto, Portugal), goat purified IgG anti-
adenosine A2A receptor antibody (200 µg/ml) was from
Santa Cruz Biotechnology-Europe (Freelab, Lisbon, Por-
tugal), and rabbit purified IgG antiadenosine A1 receptor
antibody (1.8 mg/ml) was from Affinity Bioreagents
(Golden City, CA, U.S.A.).
Animals and convulsive models
The experiments were performed using male Wistar rats
from Harlan Ibe´rica (Barcelona, Spain) weighing 240–280
g for the amygdala-kindling experiments and 160–180 g
for the kainate-injection experiments. The rats were han-
dled according to the EU guidelines for use of experimen-
tal animals (86/609/EEC); they were anesthetized under
halothane atmosphere before being killed by decapitation.
For the amygdala-kindling studies, the rats were di-
vided into three groups: control rats, fully kindled rats,
and sham-operated rats (electrode implemented but no
stimulation delivered). Kindling was achieved by inser-
tion of an electrode in the amygdala to allow chronic sub-
threshold stimulation to implement a fully kindled state,
as previously described (5). Briefly, the rats were anes-
thetized with sodium pentobarbitone 60 mg/kg (3% wt/vol
in saline) and coaxial bipolar electrodes (David Kopf)
were implanted to the left amygdala. After a postoper-
ative recovery of 1 week, animals were stimulated twice
a day (10 a.m. and 4 p.m.) with a 50 Hz, 1 s, 500 µA,
square wave with a positive pulse of 1 ms (Hugo Sachs
stimulator, March-Hugstetten, Germany). After five con-
secutive stage 5 convulsions, fully kindled rats were al-
lowed a 4-week recovery period before being killed for in
vitro studies.
For the kainate injection studies, the rats were di-
vided into two groups: control (saline-injected) and
kainate-injected animals. Kainate (10 mg/ml) was injected
intraperitoneally and the animal was placed in an observa-
tion box facing two experimenters who recorded the be-
havior changes displayed by the animals during a period of
4 hours according to the Racine’s scale. Kainate-injected
animals displayed a convulsive behavior that ranked at
stage 4 (two rats) and stage 5 (one rat), whereas two other
rats also reached stage 5 but died within the next hour,
thus being excluded from the study. The rats were then
allowed a 4-week recovery period before being killed for
in vitro studies.
Adenosine receptor binding studies in cortical
membranes
Saturation binding curves of the selective A1 receptor
antagonist, 3H-DPCPX, or of the selective A2A receptor
antagonist, 3H-SCH 58261, were performed as previously
described using whole membranes from the cerebral cor-
tex (8,15). Binding of 3H-DPCPX (0–10 nM) or of 3H-
SCH 58261 (0–10 nM) was for 2 or 1 hours, respectively,
at 37◦C, with 32–159 µg of membrane protein in a final
volume of 200 µl in an incubation solution containing
50 mM Tris-HCl and 10 mM MgCl2, pH 7.4, with 2 U/ml
adenosine deaminase. The binding reactions were stopped
by vacuum filtration through Whatman GF/C glass fiber
filters, followed by washing of the filters and reaction
tubes with 8 ml of the incubation solution, kept at 4◦C.
Radioactivity retained in the filters was then determined
after addition of 4 ml of scintillation liquid (Scintran Cock-
tail T, Wallac, Turku, Finland). Results are expressed as
specific binding, determined by subtraction of the nonspe-
cific binding, which was measured in the presence of 2 µM
XAC, and normalized per amount of protein. All binding
assays were performed in duplicate. To derive the binding
parameters from saturation curves (KD and Bmax values),
the data were fitted by a rectangular hyperbola using the
GraphPad Prism software (San Diego, CA, U.S.A.).
Western blot analysis of adenosine receptor
immunoreactivity in cortical membranes
Adenosine A1 and A2A receptor immunoreactivity was
evaluated by Western blot analysis, as previously de-
scribed (5,15) in whole membranes from the rat cere-
bral cortex. Cortical membranes solubilized in 5% SDS
were separated by SDS-PAGE (13%) and electrotrans-
ferred to polyvinylidene difluoride (PVDF) membranes
(0.45 µm from Amersham). After blocking, the mem-
branes were incubated overnight at 4◦C with either the
antiadenosine A1 receptor (1:1000 dilution) or anti-A2A
receptor antibodies (1:500 dilution), then with the alka-
line phosphatase-conjugated anti-rabbit or anti-goat sec-
ondary antibody (1:10,000 dilution from Amersham Little
Chalfont, Buckinghamshire, U.K.), and finally with En-
hanced Chemi-Fluorescence (Amersham) for 5 min, then
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analyzed densitometrically with Quantity one, Versadoc
3000 (BioRad).
Statistics
The values presented are mean ± SEM of n experi-
ments. Comparison between the different animal groups
was made using the two-tailed Mann–Whitney test. Sta-
tistical significance was considered at p < 0.05.
RESULTS
Modification of cortical A1 and A2A receptors in
kindled rats
The selective A1 receptor antagonist, 3H-DPCPX,
bound with a KD of 0.77 nM (95% confidence interval:
0.58–0.96 nM, n = 4) and a Bmax of 917 ± 60 fmol/mg
protein (n = 4) to whole membranes from the cerebral
cortex of control rats. As illustrated in Fig. 1A, there was
a decrease of 3H-DPCPX binding to cortical membranes
obtained from kindled rats. In fact, in cortical membranes
from kindled rats, the Bmax of 3H-DPCPX binding was
decreased (40.4 ± 4.4%, p < 0.05) to 546 ± 52 fmol/mg
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FIG. 1. Long-term effect of convulsions induced by amygdala kin-
dling on the density of adenosine A1 receptors in the rat cerebral
cortex. A: Average saturation binding curves with the selective A1
receptor antagonist 3H-DPCPX in cerebral cortical membranes of
control (open circles), sham-operated (open rectangles), and fully
kindled rats (filled rectangles). The ordinates represent the spe-
cific binding of 3H-DPCPX, obtained on subtraction of the nonspe-
cific binding, determined in the presence of 2 µM XAC from total
binding. The results are mean ± SEM of four experiments. B: A
Western blot comparing the A1 receptor immunoreactivity in mem-
branes from the rat cerebral cortex of control (first three lanes from
the left) and fully kindled rats (first three lanes from the right). The
SDS-PAGE gel was loaded with three different amounts of corti-
cal protein from each group of rats and is representative of three
similar separations carried out with membranes prepared from dif-
ferent animals. It is evident that the intensity of bands identified as
the A1 receptor protein is systematically lower in the membranes
derived from kindled rats when compared to the same amount of
loaded cortical membrane from control rats.
protein (n = 4), whereas the KD of 3H-DPCPX binding
was not significantly (p > 0.05) modified (KD= 0.81 nM,
95% confidence interval of 0.45–1.37 nM, n = 4). This de-
creased density of A1 receptors was not due to the surgical
procedure since the KD (0.77 nM, 95% confidence inter-
val of 0.43–1.11 nM, n = 4) and the Bmax of 3H-DPCPX
binding (866 ± 23 fmol/mg protein, n = 4) in cortical
membranes from sham-operated rats were not different (p
> 0.05) from control rats (Fig. 1A).
To confirm that there was indeed a decreased density
of A1 receptors in cerebral cortical membranes of kin-
dled compared to control rats, we compared by Western
blot analysis the immunoreactivity against A1 receptors
in membranes from cortical membranes of control and
fully kindled rats. As illustrated in Fig. 1B, there was a
decrease in the densitometrically measured anti-A1 recep-
tor immunoreactivity in cortical membranes from kindled
compared to control rats, with an average value of 19.1 ±
3.3% (n = 3).
The selective A2A receptor antagonist, 3H-SCH 58261,
bound with a KD of 0.98 nM (95% confidence interval:
0.47–1.49 nM, n = 4) and a Bmax of 27.7 ± 3.1 fmol/mg
protein (n = 4) to whole membranes from the cerebral
cortex of control rats. As illustrated in Fig. 2A, there was
a marked increase of 3H-SCH 58261 binding to cortical
membranes obtained from kindled rats. In fact, in cortical
membranes from kindled rats, the Bmax of 3H-SCH 58261
binding was nearly tripled (293 ± 34% increase, p < 0.05)
to 109.0 ± 3.5 fmol/mg protein (n = 4), with no change (p
> 0.05) of KD (1.07 nM, 95% confidence interval of 0.65–
1.50 nM, n = 4). This increased density of A2A receptors
was not due to the surgical procedure since the KD (0.88
nM, 95% confidence interval of 0.41–1.36 nM, n = 4) and
the Bmax of 3H-SCH 58261 binding (30.6 ± 3.4 fmol/mg
protein, n = 4) in cortical membranes from sham-operated
rats were not different (p > 0.05) from control rats
(Fig. 2A).
To confirm that there was indeed an increased density
of A2A receptors in cerebral cortical membranes of kin-
dled compared to control rats, we compared by Western
blot analysis the immunoreactivity against A2A receptors
in membranes from cortical membranes from control and
fully kindled rats. As illustrated in Fig. 2B, there was an
increase in the densitometrically measured anti-A2A re-
ceptor immunoreactivity in cortical membranes on kin-
dled compared to control rats, with an average value of
151 ± 12% (n = 3).
Modification of cortical A1 and A2A receptors in
kainate-injected rats
To further strength the idea that a convulsive period
caused a long-term effect on the density of adenosine re-
ceptors in the cerebral cortex, we decided to use a different
experimental paradigm to trigger convulsions. Thus, rats
were injected with kainate, which induced convulsions
Epilepsia, Vol. 46, Suppl. 5, 2005
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FIG. 2. Long-term effect of convulsions induced by amygdala kin-
dling on the density of adenosine A2A receptors in the rat cere-
bral cortex. A: Average saturation binding curves with the selec-
tive A2A receptor antagonist 3H-SCH 58261 in cerebral cortical
membranes of control (open circles), sham-operated (open rect-
angles), and fully kindled rats (filled rectangles). The ordinates
represent the specific binding of 3H-SCH 58261, obtained on sub-
traction of the nonspecific binding, determined in the presence of
2 µM XAC from total binding. The results are mean ± SEM of
four experiments. B: A Western blot comparing the A2A receptor
immunoreactivity in membranes from the rat cerebral cortex of
control (right lane) and fully kindled rats (left lane). The SDS-
PAGE gel was loaded with 200 µg of cortical protein from each
group of rats and is representative of three similar separations
carried out with membranes prepared from different animals. It is
evident that the intensity of bands identified as the A2A receptor
protein is higher in the membranes derived from kindled compared
to control rats.
reaching a stage 4-5 between 30 and 240 min after kainate
injection, and the density of cortical A1 and A2A receptors
was evaluated after 30 days. As was observed in amygdala-
kindled rats, there was a decrease in the binding density
of the selective A1 receptor antagonist, 3H-DPCPX. Thus,
3H-DPCPX bound with a KD of 1.04 nM (95% confidence
interval: 0.50–1.51 nM, n = 3) and a Bmax of 907 ± 4.5
fmol/mg protein (n = 3) to whole membranes from the
cerebral cortex of control (i.e., saline-injected rats). As
illustrated in Fig. 3A, in cortical membranes from kin-
dled rats, the Bmax of 3H-DPCPX binding was decreased
to 719 ± 15 fmol/mg protein (20.7 ± 0.5% decrease, p
< 0.05, n = 3) without change in KD (KD= 1.03 nM,
95% confidence interval of 0.82–1.24 nM, n = 3). This
decreased density of A1 receptors was also confirmed by
Western blot analysis. In fact, as illustrated in Fig. 3B,
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FIG. 3. Long-term effect of convulsions caused by the intraperi-
toneal injection of kainate on the density of adenosine A1 re-
ceptors in the rat cerebral cortex. A: Average saturation binding
curves with the selective A1 receptor antagonist 3H-DPCPX in
cerebral cortical membranes of control (open circles) and kainate-
induced kindled rats (filled rectangles). The ordinates represent
the specific binding of 3H-DPCPX, obtained on subtraction of the
nonspecific binding, determined in the presence of 2 µM XAC from
total binding. The results are mean ± SEM of three experiments.
B: A Western blot comparing the A1 receptor immunoreactivity
in membranes from the rat cerebral cortex of control (first three
lanes from the left) and fully kindled rats (first three lanes from the
right). The SDS-PAGE gel was loaded with three different amounts
of cortical protein from each group of rats and is representative
of three similar separations carried out with membranes prepared
from different animals. It is evident that the intensity of bands iden-
tified as the A1 receptor protein is systematically lower in the mem-
branes derived from kainate-injected rats when compared to the
same amount of loaded cortical membrane from control rats.
there was a decrease in the densitometrically measured
anti-A1 receptor immunoreactivity in cortical membranes
of kainate-injected compared to control rats, with an av-
erage value of 12.7 ± 5.7% (n = 3).
Convulsions induced by kainate also caused a marked
upregulation of A2A receptors, as occurred in kindled rats.
In fact, as illustrated in Fig. 4, there was a near doubling
(159 ± 32% increase, p < 0.05) of the density of 3H-SCH
58261 binding in kainate-injected rats (Bmax of 70.2 ±
5.8 fmol/mg protein, n = 3) compared to control (Bmax of
26 ± 2.9 fmol/mg protein, n = 3), with no change in KD
(0.89 nM, 95% confidence interval: 0.78–1.01 nM, n =
3, in control vs. 0.91 nM, 95% confidence interval: 0.59–
1.21 nM, n = 3, in kainate-injected rats). This increased
density of A2A receptors was also confirmed by Western
blot analysis. In fact, as illustrated in Fig. 4B, there was
a marked increase in the densitometrically measured anti-
A2A receptor immunoreactivity in cortical membranes of
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FIG. 4. Long-term effect of convulsions caused by the intraperi-
toneal injection of kainate on the density of adenosine A2A re-
ceptors in the rat cerebral cortex. A: Average saturation bind-
ing curves with the selective A2A receptor antagonist 3H-SCH
58261 in cerebral cortical membranes of control (open circles)
and kainate-induced kindled rats (filled rectangles). The ordinates
represent the specific binding of 3H-SCH 58261, obtained on sub-
traction of the nonspecific binding, determined in the presence of
2 µM XAC from total binding. The results are mean ± SEM of
three experiments. B: A Western blot comparing the A2A recep-
tor immunoreactivity in membranes from the rat cerebral cortex of
control (right lane) and kainate-injected rats (left lane). The SDS-
PAGE gel was loaded with 180 µg of cortical protein from each
group of rats and is representative of three similar separations
carried out with membranes prepared from different animals. It is
evident that the intensity of bands identified as the A2A receptor
protein is higher in the membranes derived from kindled compared
to control rats.
kainate-injected compared to control rats, with an average
value of 79.6 ± 7.0% (n = 3).
DISCUSSION
The neuromodulator adenosine has been associated
with epileptic phenomena [reviewed in (2)] since there
is a massive amount of adenosine released during seizures
(16) and manipulation of the activity of either A1 [re-
viewed in (2)] or A2A receptors (10) affects convulsive
behavior. We now found that convulsive behavior trig-
gers a long-term decrease of A1 receptor density and
an increase of A2A receptor density in the cerebral cor-
tex. This conclusion was reached using two different and
well-established paradigms to trigger convulsive behav-
ior, amygdala kindling (13) and kainate injection (14),
and two different experimental approaches to measure the
density of adenosine A1 and A2A receptors, i.e., radioli-
gand binding with selective antagonists and using selec-
tive antibodies against each adenosine receptor subtype.
Thus, the observed remarkable qualitative similarity be-
tween the findings obtained when using two different ways
to trigger convulsions and two different methods to eval-
uate changes in adenosine receptor density emphasizes
the robustness of this major conclusion, i.e., that convul-
sive behavior causes a long-term increase in A2A receptor
density and a decrease of the density of A1 receptors.
Several studies have shown that A1 receptors undergo
desensitization on prolonged activation (17–19), which
is expected due to the massive and prolonged increase
of extracellular adenosine occurring upon ictal activity
(16,20,21). However, previous studies failed to reach
an agreement on the effects of seizure activity on the
density of A1 receptors in the brain [reviewed in (4)].
In fact, most studies evaluating acute or short-term ef-
fects (i.e., after 24 h) of convulsions most commonly
found an increase in the density of A1 receptors in dif-
ferent brain regions, either upon induction of seizures
with pentylenetetrazole (22,23), bicuculline (24,25), or
3-mercaptopropionate (26). In contrast, no acute or short-
term changes in the density of brain A1 receptors were
found after electroconvulsive stimulation (27,28) or upon
intraperitoneal injection of kainate (29). Changes in the
density of A1 receptors occurring 2–15 days after the ob-
servation of convulsive behavior also seem to depend on
the strategy used to trigger convulsions. Thus, convulsions
triggered by pentylenetetrazole (22) or repeated electro-
convulsive stimulation (27,28) enhanced the density of A1
receptors in most brain regions, whereas no measurable
modification of A1 receptor density was reported upon
amygdala kindling (30)] or kainate injection (29,31). In-
terestingly, most studies seem to find a long-term decrease
in the density of adenosine A1 receptors, at least in the hip-
pocampus (5,29,31). Thus, there is a general trend indicat-
ing that convulsive behavior leads to a long-term decrease
in the density of A1 receptors, as we now report has oc-
curred in the cerebral cortex. This conclusion is in general
agreement with the development of tolerance in relation to
the anticonvulsive effects of A1 receptor agonists (3,32).
However, the currently observed decrease of A1 recep-
tor density does not necessarily exclude A1 receptors as
potential targets for the development of new anticonvul-
sant drugs. In fact, while the efficiency of most anticon-
vulsants decreases markedly with increasing severity of
seizures, A1 receptor activation is able to suppress seizures
in an animal model of pharmacoresistant epilepsy (33).
This may be understood if one keeps in mind that seizures
cause a long-term greater modification of the extracellular
levels of adenosine able to activate A1 receptors than a de-
sensitization of responses mediated by A1 receptors [(5),
reviewed in (4)]. This suggests that strategies aimed at in-
creasing the extracellular levels of adenosine may be more
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effective than using A1 receptor agonists (34,35), which
also have the disadvantages of poor brain penetration and
causing potent peripheral side effects (36).
In contrast to the well-defined potential of A1 receptor
activation to control seizures, the role of A2A receptors is
less well established. In fact, some reports with purport-
edly selective A2A receptor agonists consistently observed
anticonvulsant effects (32,37–39). However, despite the
established presence of low amounts of A2A receptors in
cortical brain regions, it has recently been concluded that
A2A receptor agonists (like CGS 21680) mostly bind to
A1 rather than to A2A receptors in cortical regions (8).
This suggests that the activation of A1 receptors might
underlie the anticonvulsive effects of these purportedly
selective A2A receptor agonists (40). However, there are
reasons to believe that A2A receptors might play a role in
the control of seizures and/or epileptogenesis. In fact, the
group of Vaugeois showed that pharmacological block-
ade or genetic deletion of A2A receptors decrease ethanol
withdrawal-induced seizures in mice (10). Likewise, it has
systematically been shown that blockade of A2A receptors
is neuroprotective in different noxious situations that in-
volve limbic or cortical degeneration [reviewed in (9)], as
is the case of temporal lobe epilepsy (41). This prelimi-
nary evidence, together with the presently observed robust
increase in the density of adenosine A2A receptors in the
cerebral cortex of rats that had undergone a convulsive
period, make A2A receptor antagonists an attractive novel
class of anticonvulsive drugs.
In conclusion, the presently observed long-term de-
crease in the density of A1 receptors and the parallel in-
crease of the density of A2A receptors in the cerebral cor-
tex provide a preliminary rationale for the development
of novel anticonvulsive strategies targeting the adenosine
neuromodulatory systems, which might be based on the
combined use of strategies to burst the extracellular levels
of adenosine to activate inhibitory A1 receptors together
with antagonists of facilitatory A2A receptors.
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